Raymond Akers has resgined from the board of directors of Akers Biosciences, effective immediately. In a document filed with the US Securities and Exchange Commission dated June 1, the firm said that it believes Akers resigned due to "his significant differences with other members of the board regarding management of the company, its accounting and business practices, and its counsel." Last week, the company said that it had been granted a 180-day extension to meet a listing requirement of the Nasdaq calling for a minimum $1 per share closing bid price for 10 consecutive business days. The company added that the board's audit committee has been reviewing certain revenue recognition items for Q1 2018 and previous quarters. "The company believes Dr. Akers has not been fully cooperative in connection with such review," it said in its SEC document.